Philogen S.p.A. (BIT:PHIL)

Italy flag Italy · Delayed Price · Currency is EUR
21.50
+0.10 (0.47%)
Aug 14, 2025, 9:38 AM CET
-1.38%
Market Cap 867.14M
Revenue (ttm) 77.65M
Net Income (ttm) 45.29M
Shares Out 40.33M
EPS (ttm) 1.12
PE Ratio 19.20
Forward PE 2.39
Dividend n/a
Ex-Dividend Date n/a
Volume 5,127
Average Volume 7,255
Open 21.60
Previous Close 21.50
Day's Range 21.50 - 21.60
52-Week Range 16.50 - 27.80
Beta 0.14
RSI 40.15
Earnings Date Sep 23, 2025

About Philogen

Philogen S.p.A., a biotechnology company, develops drugs for oncology and chronic inflammatory diseases in Switzerland and the European Union. The company develops Nidlegy, a combination of the immunocytokines L19IL2 and L19TNF, which is in Phase III trial for the intralesional treatment of locoregional melanoma and non-melanoma skin cancers; Fibromun, a human immunomodulatory product consisting of L19 antibody and TNF in Phase III trial to treat soft tissue sarcoma, leiomyosarcoma, and glioma; and Darleukin (L19IL2), a human immunostimulatory ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1996
Employees 183
Stock Exchange Borsa Italiana
Ticker Symbol PHIL
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.